Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: Its pharmacokinetic application

Journal of Pharmaceutical and Biomedical Analysis

Volumn 90, Issue , 2014, Pages 64-71

  Bonde, S L ^a   Bhadane, R P ^a   Gaikwad, Avinash ^b   Gavali, S R ^b   Katale, D U ^b   Narendiran, A S ^b  

^a Modern Education Society's   (India)

^b Bioanalytical Department of VerGo Clinicals   (India)

Author keywords

Bioequivalence; Fluoxetine; Human plasma; LC MS MS; Olanzapine

Indexed keywords

AMMONIUM ACETATE; FLUOXETINE; METHANOL; OLANZAPINE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALIBRATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; ROOM TEMPERATURE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOEQUIVALENCE; FLUOXETINE; HUMAN PLASMA; LC-MS/MS; OLANZAPINE;

ADULT; BENZODIAZEPINES; CALIBRATION; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DRUG COMBINATIONS; FLUOXETINE; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEROTONIN UPTAKE INHIBITORS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 84890286108     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.10.033     Document Type: Article

References (29)

1. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 2001, 158:131-134.
2. Mathews J.D., Bottonari K.A., Polania L.M., Mischoulon D., Dording C.M., Irvin R., Fava M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Journal of Clinical Psychiatry 2002, 63:1164-1170.
3. Scott L.J., Perry C.M. Interferon-alpha-2b ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002, 62:507-556.
4. Leon Duscia J., Peter Hacketta L., Lind Fellows M., Kenneth Iletta F. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. Journal of Chromatography B 2002, 773:191-197.
5. David Boulton W., John Markowitzb S., Lindsay DeVane C. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. Journal of Chromatography B: Biomedical Sciences and Applications 2001, 759:319-323.
6. Arrigo D., Concetta, Migliardi, Gaetana Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Therapeutic Drug Monitoring 2006, 28:388-393.
7. Raggi M.A., Mandrioli R., Sabbioni C., Ghedini N. Determination of olanzapine and desmethylolanzapine in the plasma of schizophrenic patients by means of an improved HPLC method with amperometric detection. Chromatographia 2001, 54:203-207.
8. Jenting Andre Chiu B., Ronald Franklin Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis 1996, 14:609-615.
9. Aravagiri M., Ames D., Wirshing W.C., Marder S.R. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Therapeutic Drug Monitoring 1997, 19:307-313.
10. John Catlow T., Richard Barton D., Matt Clements A., Gillespie T. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B: Biomedical Sciences and Applications 1995, 668:85-90.
11. Augusta Raggi M., Casamentia G., Mandriolia R., Volterra V. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. Journal of Chromatography B: Biomedical Sciences and Applications 2001, 750:137-146.
12. Chiu J.A., Franklin R.B. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis 1996, 14:609-615.
13. Dinesh Patel S., Naveen Sharma C., Mukesh Patel N., Bhavin Patel S., Shrivastav P., Sanyal M. LC-MS/MS assay for olanzapine in human plasma and its application to a bioequivalence study. Acta Pharmaceutica Sinica B 2012, 2:481-494.
14. Nielsen M.K.K., Johansen S.S. Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. Journal of Analytical Toxicology 2009, 33:15-26.
15. Nirogi R.V., Kandikere V.N., Shukla M., Mudigonda K., Maurya S., Boosi R., Yerramilli A. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2006, 41:935-942.
16. Bogusz M.J., Krugera K.D., Maier R.D. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 1999, 732:257-269.
17. Higashia Y., Gaoa R., Fujii Y. Determination of fluoxetine and norfluoxetine in human serum and urine by HPLC using a cholester column with fluorescence detection. Journal of Liquid Chromatography and Related Technologies 2009, 32:1141-1151.
18. Erturk S., Çetin S.M., Atmaca S., Ersoy L., Baktr G.L. A sensitive HPLC method for the determination of fluoxetine and norfluoxetine in human plasma with fluorescence detection. Therapeutic Drug Monitoring 2005, 27:38-43.
19. Guo X., Fukushima T., Famei K.I. Determination of fluoxetine and norfluoxetine in rat plasma by HPLC with pre-column derivatization and fluorescence detection. Biomedical Chromatography 2003, 17:1-5.
20. de Freitas D.F., Porto C.E., Vieira E.P., de Siqueira M.E. Three-phase, liquid-phase microextraction combined with high performance liquid chromatography-fluorescence detection for the simultaneous determination of fluoxetine and norfluoxetine in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2010, 51:170-171.
21. Silva B.J., Lanças F.M., Queiroz M.E. Determination of fluoxetine and norfluoxetine enantiomers in human plasma by polypyrrole-coated capillary in-tube solid-phase microextraction coupled with liquid chromatography-fluorescence detection. Journal of Chromatography A 2009, 1216:8590-8597.
22. Unceta N., Barrondo S., de Azua I.R., Alberto G.-C., Aranzazu Goicolea M. Determination of fluoxetine, norfluoxetine and their enantiomers in rat plasma and brain samples by liquid chromatography with fluorescence detection. Journal of Chromatography B 2007, 852:519-528.
23. Guo X., Fukushima T., Li F., Imai K. Determination of fluoxetine and norfluoxetine in rat plasma by HPLC with pre-column derivatization and fluorescence detection. Biomedical Chromatography 2003, 17:1-5.
24. Li C., Ji Z., Nan F., Shao Q., Liu P., Dai J., Zhen J. Liquid chromatography/tandem mass spectrometry for the determination of fluoxetine and its main active metabolite norfluoxetine in human plasma with deuterated fluoxetine as internal standard. Rapid Communications in Mass Spectrometry 2002, 16:1844-1850.
25. Sutherland F.C., Badenhorst D., de Jager A.D., Scanes T., Hundt H.K., Swart K.J., Hundt A.F. Sensitive liquid chromatographic-tandem mass spectrometric method for the determination of fluoxetine and its primary active metabolite norfluoxetine in human plasma. Journal of Chromatography A 2001, 914:45-51.
26. Djordjevic S., Kovacevic I., Miljkovic B., Vuksanovic J., Pokrajac M. Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. Farmaco 2005, 60:345-349.
27. Eerkes A., Weng N., King M., Du A., Shou W.Z. A sensitive and high-throughput LC/MS/MS using a silica column and an aqueous-organic mobile phase for the analysis of fluoxetine and norfluoxetine in human plasma. Journal of Liquid Chromatography and Related Technologies 2005, 25:1215-1227.
28. Gopinath S., Kumar R.S., Alexander S., Danabal P. Development of a rapid and sensitive SPE-LC-MS/MS method for the simultaneous estimation of fluoxetine and olanzapine in human plasma. Biomedical Chromatography 2012, 26:1077-1082.
29. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM) Guidance for Industry, Bionanlytical Method Validation 2001 May, Available from: http://www.fda.gov/downloads/Drugs/Guidance Compliance Regulatory Information/Guidances/UCM070107.